Literature DB >> 32022823

Diastolic Heart Failure in Patients With the Fontan Circulation: A Review.

Werner Budts1, William J Ravekes2, David A Danford3, Shelby Kutty2.   

Abstract

The Fontan circulation, accomplished by direct surgical connection of the vena cavae to the pulmonary arteries, can be an effective palliation for patients with a single ventricle. However, failure of the Fontan circulation can result from mechanical obstruction, cardiac arrhythmias, increasing pulmonary vascular resistance, or deteriorating ventricular performance. Although systolic ventricular failure can usually be identified by a combination of clinical signs, symptoms, and imaging findings, diastolic ventricular dysfunction is likely an underrecognized cause of Fontan failure. Methods for detection of impaired diastolic function in a single ventricle are evolving, and established techniques appropriate in the biventricular heart lack validation in single ventricle. Association of biomarkers, cardiac magnetic resonance, and echocardiographic findings with invasively acquired pressure-volume loop data in humans may offer a way forward to accurate, noninvasive diagnosis. Today, therapy for severe diastolic ventricular dysfunction in the Fontan circulation is often disappointing and may require consideration of a ventricular assist device or even cardiac transplant. Progress toward improved outcomes of the Fontan palliation likely depends on successful innovation in primary prevention strategies and the development of more effective pharmacotherapy.

Entities:  

Year:  2020        PMID: 32022823     DOI: 10.1001/jamacardio.2019.5459

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  9 in total

Review 1.  Therapeutic Approaches in Heart Failure with Preserved Ejection Fraction (HFpEF) in Children: Present and Future.

Authors:  Bibhuti B Das
Journal:  Paediatr Drugs       Date:  2022-05-02       Impact factor: 3.022

2.  Factors associated with psychological resilience in patients with chronic heart failure and efficacy of psycho-cardiology intervention.

Authors:  Xinkang Wang; Jie Gao; Jianchun Zhang; Yanqiu Yang; Weixin Zhang; Xiling Zhang; Lihong Lu; Rehua Wang
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

Review 3.  Heart Failure with Preserved Ejection Fraction in Children.

Authors:  Bibhuti Das; Shriprasad Deshpande; Jyothsna Akam-Venkata; Divya Shakti; William Moskowitz; Steven E Lipshultz
Journal:  Pediatr Cardiol       Date:  2022-08-17       Impact factor: 1.838

Review 4.  Heart Failure in Complex Congenital Heart Disease of the Adult.

Authors:  Anisa Chaudhry; Julia Selwyn; Elizabeth Adams; Elisa A Bradley
Journal:  Curr Cardiol Rep       Date:  2022-10-05       Impact factor: 3.955

5.  Failing Fontan.

Authors:  Om Prakash Yadava; Richard A Jonas
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-01-04

6.  Diastolic Dysfunction With Preserved Ejection Fraction After the Fontan Procedure.

Authors:  Shahryar M Chowdhury; Eric M Graham; Carolyn L Taylor; Andrew Savage; Kimberly E McHugh; Stephanie Gaydos; Arni C Nutting; Michael R Zile; Andrew M Atz
Journal:  J Am Heart Assoc       Date:  2022-01-13       Impact factor: 6.106

Review 7.  Long-term management of Fontan patients: The importance of a multidisciplinary approach.

Authors:  Diletta Martino; Caterina Rizzardi; Serena Vigezzi; Chiara Guariento; Giulia Sturniolo; Francesca Tesser; Giovanni di Salvo
Journal:  Front Pediatr       Date:  2022-08-25       Impact factor: 3.569

8.  Myocardial fibrosis, diastolic dysfunction and elevated liver stiffness in the Fontan circulation.

Authors:  Tarek Alsaied; Ryan A Moore; Sean M Lang; Vien Truong; Adam M Lubert; Gruschen R Veldtman; Konstantin Averin; Jonathan R Dillman; Andrew T Trout; Wojciech Mazur; Michael D Taylor; Quan He; David Ls Morales; Andrew N Redington; Bryan H Goldstein
Journal:  Open Heart       Date:  2020-10

Review 9.  Primary Cilia and Their Role in Acquired Heart Disease.

Authors:  Zachariah E Hale; Junichi Sadoshima
Journal:  Cells       Date:  2022-03-11       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.